ASH: Argenx cues up a second use for efgartigimod
pharmaphorum
DECEMBER 12, 2022
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting. Sales of Argenx’ drug reached $131 million in the third quarter of 2022, and $227 million in the first nine months of the year.
52 
Let's personalize your content